Trials
Search / Trial NCT06441708

Neutrophil Extracellular Traps (NETs) Mediated Killing of Carbapenem-resistant Pseudomonas Aeruginosa.

Launched by ASSIUT UNIVERSITY · Jun 3, 2024

Apply for Trial

Trial Information

Current as of March 14, 2025

Not yet recruiting

Keywords

ClinConnect Summary

Pseudomonas aeruginosa is one of the most common pathogens in healthcare-associated infections worldwide, causing ventilator-associated pneumonia, urinary tract infections in patients with long-term urinary catheterization, wound infections, bloodstream infections, and otitis (reynolds and kollef, 2021).

Carbapenem-resistant-P. aeruginosa infection is a prominent disease connected to healthcare due to multiple mechanisms, such as target alteration, active efflux, decreased permeability, and enzyme degradation (Tenover et al., 2022).

Neutrophils are the most prominent cellular component of...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • • isolates will be isolated from different clinical samples including wound respiratory tract urine and blood. _carbapenem-resistant P. aeruginosa isolates.
  • Exclusion Criteria:
  • • _carbapenem-sensitive P. aeruginosa isolates.

About Assiut University

Assiut University, a prominent academic institution located in Egypt, is dedicated to advancing medical research and clinical trials that enhance healthcare outcomes. With a strong emphasis on innovation and collaboration, the university engages in a wide array of clinical studies across various disciplines, aiming to contribute valuable insights into disease prevention, diagnosis, and treatment. Assiut University's commitment to ethical research practices and rigorous scientific methodology ensures the integrity and reliability of its clinical trials, ultimately benefiting both the local community and the global medical landscape.

Locations

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0